AZD-0364

oral inhibitor of ERK1 and ERK2

Also Known As:

(6R)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)-4-pyrimidinyl)-6,7-dihydroimidazo(1,2-a)pyrazin-8(5H)-one; AZD0364; imidazo(1,2-a)pyrazin-8(5H)-one, 7-((3,4-difluorophenyl)methyl)-6,7-dihydro-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)-4-pyrimidinyl)-, (6R)-

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Davies, Emma J: 2 articles (01/2021 - 12/2019)
2.	Farrington, Paul: 2 articles (01/2021 - 12/2019)
3.	Flemington, Vikki: 2 articles (01/2021 - 12/2019)
4.	Gibbons, Francis D: 2 articles (01/2021 - 12/2019)
5.	Hanson, Lyndsey: 2 articles (01/2021 - 12/2019)
6.	Hopcroft, Philip: 2 articles (01/2021 - 12/2019)
7.	Jones, Clifford D: 2 articles (01/2021 - 12/2019)
8.	Lindsay, Nicola: 2 articles (01/2021 - 12/2019)
9.	Roberts, Karen: 2 articles (01/2021 - 12/2019)
10.	Simpson, Iain: 2 articles (01/2021 - 12/2019)

Related Diseases

1.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/17/2020 - "The aim of this study was to investigate the effect of the combination of ERK1/2 inhibitor AZD0364 and PI3K inhibitor ZSTK474 on acute lymphoblastic leukemia (ALL) REH, MOLT-4, acute myeloid leukemia (AML) MOLM-14, and chronic myeloid leukemia (CML) K562 cell lines. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/17/2020 - "The aim of this study was to investigate the effect of the combination of ERK1/2 inhibitor AZD0364 and PI3K inhibitor ZSTK474 on acute lymphoblastic leukemia (ALL) REH, MOLT-4, acute myeloid leukemia (AML) MOLM-14, and chronic myeloid leukemia (CML) K562 cell lines. "
3.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/17/2020 - "The aim of this study was to investigate the effect of the combination of ERK1/2 inhibitor AZD0364 and PI3K inhibitor ZSTK474 on acute lymphoblastic leukemia (ALL) REH, MOLT-4, acute myeloid leukemia (AML) MOLM-14, and chronic myeloid leukemia (CML) K562 cell lines. "
4.	Neoplasms (Cancer) 01/01/2021 - "The AZD0364 and selumetinib combination also results in significant tumor regressions in multiple KRAS-mutant xenograft models. " 01/01/2021 - "In multiple in vivo xenograft models, AZD0364 showed dose- and time-dependent modulation of ERK1/2-dependent signaling biomarkers resulting in tumor regression in sensitive BRAF- and KRAS-mutant xenografts. " 01/01/2021 - "AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib."
5.	Leukemia 07/17/2020 - "The results showed that incubation with both AZD0364 and ZSTK474 inhibited cell viability, increased reactive oxygen species (ROS) production, and induced apoptosis in leukemia cells. "

Related Drugs and Biologics

1.	ZSTK474
2.	Mitogen-Activated Protein Kinase Kinases (MEKs)
3.	Reactive Oxygen Species (Oxygen Radicals)
4.	Biomarkers (Surrogate Marker)
5.	AZD 6244

Related Therapies and Procedures

1.	Therapeutics